LDC-backed clinical research organisation Panthera Biopartners is expanding its clinical research capacity in Glasgow, as it continues to grow its UK and European operations.
The expansion is supported by LDC, the private equity investor which backed Panthera in 2025, alongside existing minority shareholder BGF.
The new Glasgow capacity will strengthen Panthera’s ability to deliver clinical research programmes, providing additional resources for pharmaceutical and biotechnology companies conducting clinical trials.
The development forms part of Panthera’s wider growth strategy, with the business looking to expand its clinical research network and increase its capacity to support the development of new treatments.
LDC’s investment in Panthera forms part of its wider strategy of backing established UK mid-market firms with ambitions to grow through investment, operational development and expansion.
Stuart Young, chief executive officer of Panthera, said: “We are delighted to celebrate the official opening of our expanded Glasgow centre alongside colleagues and partners from across Scotland’s healthcare and life sciences community.”
“Glasgow has an outstanding reputation for medical research and innovation. This investment increases our capacity to deliver commercial clinical trials and reflects our confidence in the city’s research expertise.”
He added: “Our priority is to help pharmaceutical sponsors and CROs recruit more eligible patients quickly, meeting and exceeding enrolment targets – a critical factor in keeping clinical development programmes on schedule.
“Our expanded Glasgow centre combines increased capacity with an experienced research team to accelerate recruitment, broaden patient access and deliver high-quality studies. This investment forms part of our wider growth across the UK and Europe, where Panthera has recently become Hungary’s largest independent clinical trial site management organisation.”











